Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Tokyo  >  DAIICHI SANKYO COMPANY, LIMITED    4568   JP3475350009

News SummaryMost relevantAll newsSector newsTweets 

Daiichi Sankyo Co : Daiichi Sankyo to Develop Narcotic Analgesic Hydromorphone Hydrochloride in Japan

share with twitter share with LinkedIn share with facebook
share via e-mail
03/24/2012 | 07:59am CET

For Immediate Release
Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, President and Representative Director
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges) Please address inquiries to Toshiaki Sai, General Manager, Corporate Communications Department
Telephone: +81-3-6225-1126

Daiichi Sankyo to Develop Narcotic Analgesic Hydromorphone Hydrochloride in Japan Tokyo, Japan (March 23, 2012) - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it will develop hydromorphone hydrochloride, a narcotic analgesic that has yet to be approved in Japan.

Hydromorphone hydrochloride is an opiate, narcotic analgesic that has been available outside of Japan for over 80 years. Although it is the standard for pain management for cancer pain treatment according to WHO guidelines, hydromorphone hydrochloride has yet to be approved in Japan.
Mundipharma K.K. had been requested by the Study Group on Unapproved and Off-label Drugs of High Medical Need* to develop hydromorphone hydrochloride in Japan, but after subsequent discussions it was decided that Daiichi Sankyo would develop the drug instead. The development of hydromorphone hydrochloride will contribute to the improvement of pain management options in Japan, and Daiichi Sankyo, through its commitment to corporate social responsibility, will continue to work to make unapproved and off-label drugs available in Japan in order to further contribute to medical treatment options for patients.
*A study group set up by Japan's Ministry of Health, Labour and Welfare to promote development by pharmaceutical companies of unapproved and off-label drugs in Japan that have been approved in the United States and Europe.

distributed by

This press release was issued by Daiichi Sankyo Co. Ltd. and was initially posted at http://www.daiichisankyo.com/news/20120321_376_E2.pdf . It was distributed, unedited and unaltered, by noodls on 2012-03-24 07:53:56 AM. The issuer is solely responsible for the accuracy of the information contained therein.

share with twitter share with LinkedIn share with facebook
share via e-mail
01/19 KITE PHARMA : Establishes a Strategic Partnership With Daiichi Sankyo to Develop..
01/19 DAIICHI SANKYO : Initiates Phase 1/2 Study of Novel Antibody Drug Conjugate U3-1..
01/18 DAIICHI SANKYO : Announces Participation in the Global Initiative, Access Accele..
01/18 WON'T PURSUE STAKE SALE IN FORTIS : Ex-ranbaxy promoters assure hc
01/17 FORTIS HEALTHCARE : Daiichi moves hc to block fortis stake sale
01/12 DAIICHI SANKYO : Findings from Daiichi Sankyo in the Area of Immunoglobulins Rep..
01/12 DAIICHI SANKYO : Shuts india r&d arm
01/12 DAIICHI SANKYO : Shuts 170-man research unit
01/10 DAIICHI SANKYO : Announces Reorganization of Research & Development System
01/09 DAIICHI SANKYO : Establishes Strategic Partnership for Cellular Therapy Pipeline..
More news
Sector news : Pharmaceuticals - NEC
01/20 European shares ease ahead of Trump inauguration
01/20 Bristol-Myers shares fall on lung cancer timeline setback
01/19DJRival to EpiPen Allergy Treatment to Return to Market--Update
01/19DJRival to EpiPen Allergy Treatment to Return to Market
01/19 Davos CEOs 'go local' on supply chain in Trump era
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01/18 Daiichi launches Japan-based study of breast cancer candidate U3-1402
01/10 RHEUMATOID ARTHRITIS : The Big 3 And The Future
01/09 Kite Pharma signs deal with Daiichi Sankyo to commercialize lead product cand..
2016 FDA OKs Teva's generic version of blood pressure med Tribenzor
2016 6 Ways To Profit From This Looming Disaster
Financials ( JPY)
Sales 2017 928 677 M
EBIT 2017 -
Net income 2017 68 653 M
Finance 2017 298 760 M
Yield 2017 2,80%
P/E ratio 2017 24,03
P/E ratio 2018 25,56
EV / Sales 2017 1,59x
EV / Sales 2018 1,66x
Capitalization 1 771 110 M
More Financials
Duration : Period :
DAIICHI SANKYO COMPANY, LI Technical Analysis Chart | 4568 | JP3475350009 | 4-Traders
Full-screen chart
Technical analysis trends DAIICHI SANKYO CO...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 11
Average target price 2 360  JPY
Spread / Average Target -5,5%
Consensus details
EPS Revisions
More Estimates Revisions
Joji Nakayama President, CEO & Representative Director
Kentaro Takamura IR Contact, Manager-Finance & Accounting
Glenn J. Gormley Senior Managing Executive Officer, Head-R&D
Masahiko Ohtsuki Executive Officer & Senior Manager-Research
Kazunori Hirokawa Representative Director, VP & GM-Administration
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-0.92%310 549
ROCHE HOLDING LTD.1.29%200 499
PFIZER INC.-2.19%192 792
NOVARTIS AG-4.32%185 152
MERCK & CO., INC.6.22%172 404
More Results